Author

M. Duran-Frigola

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

L. Mateo· 2 shared P. Aloy· 2 shared A. Califano· 1 shared A. Fernandez-Torras· 1 shared A. Gris-Oliver· 1 shared A. Pessia· 1 shared B. Szalai· 1 shared C. Karan· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

L. Mateo

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCell Reports MedicinePeer-reviewedJan 1, 2022

A Community Challenge for Pancancer Drug Mechanism of Action Inference from Perturbational Profile Data

E. F. Douglass, R. J. Allaway, B. Szalai…·A. Califano

The paper hosts a DREAM Challenge to evaluate computational models for predicting drug polypharmacology using perturbational profile data from 32 kinase inhibitors.

DOI 10.1016/j.xcrm.2021.100492

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivSep 18, 2020

Personalized Cancer Therapy Prioritization Based on Driver Alteration Co-occurrence Patterns

L. Mateo, M. Duran-Frigola, A. Gris-Oliver…·P. Aloy

The paper identifies actionable genomic vulnerabilities in cancer by analyzing driver alteration co-occurrence patterns and validates predictions in mice, improving drug response modeling from patient data.

DOI 10.1186/s13073-020-00774-x

mousewhole-genome sequencing

𝕏 PostBluesky